Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

Hassan Raffit; Alley Evan; Kindler Hedy; Antonia Scott; Jahan Thierry; Honarmand Somayeh; Nair Nitya; Whiting Chan C.; Enstrom Amanda; Lemmens Ed; Tsujikawa Takahiro; Kumar Sushi; Choe Gina; Thomas Anish; McDougall Katherine; Murphy Aimee L.; Jaffee Elizabeth; Coussens Lisa M.; Brockstedt Dirk G.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

【24h】

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

机译：患有宫廷素（CRS-207）的活衰减，患有恶性胸膜间皮瘤患者的临床响应

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with poor prognosis. CRS-207 is a live-attenuated Listeria monocytogenes engineered to express mesothelin, a tumor-associated antigen highly expressed in MPM. CRS-207 induces antitumor immune responses and increases susceptibility of neoplastic cells to immune-mediated killing.

机译：目的：恶性胸膜间皮瘤（MPM）是一种与预后差相关的侵略性癌症。 CRS-207是一种活化的李斯特替氏菌，其设计以表达培育素，以MPM高度表达的肿瘤相关的抗原。 CRS-207诱导抗肿瘤免疫应答，并增加肿瘤细胞对免疫介导的杀灭的敏感性。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2019年第19期|共12页
作者
Hassan Raffit; Alley Evan; Kindler Hedy; Antonia Scott; Jahan Thierry; Honarmand Somayeh; Nair Nitya; Whiting Chan C.; Enstrom Amanda; Lemmens Ed; Tsujikawa Takahiro; Kumar Sushi; Choe Gina; Thomas Anish; McDougall Katherine; Murphy Aimee L.; Jaffee Elizabeth; Coussens Lisa M.; Brockstedt Dirk G.;
展开▼
作者单位

NCI Thorac &

GI Malignancies Branch Bethesda MD 20892 USA;

Univ Penn Div Hematol Oncol Philadelphia PA 19104 USA;

Univ Chicago Gastrointestinal Oncol Programs Sect Hematol Oncol Chicago IL 60637 USA;

H Lee Moffitt Canc Ctr &

Res Inst Thorac Oncol Dept Tampa FL USA;

Univ Calif San Francisco Dept Med Div Hematol Oncol San Francisco CA 94143 USA;

Aduro Biotech Inc Berkeley CA USA;

Aduro Biotech Inc Berkeley CA USA;

Aduro Biotech Inc Berkeley CA USA;

Aduro Biotech Inc Berkeley CA USA;

Aduro Biotech Inc Berkeley CA USA;

Oregon Hlth &

Sci Univ Knight Canc Inst Dept Cell Dev &

Canc Biol Portland OR 97201 USA;

Oregon Hlth &

Sci Univ Knight Canc Inst Dept Cell Dev &

Canc Biol Portland OR 97201 USA;

Oregon Hlth &

Sci Univ Knight Canc Inst Dept Cell Dev &

Canc Biol Portland OR 97201 USA;

NCI Dev Therapeut Branch Bethesda MD 20892 USA;

Aduro Biotech Inc Berkeley CA USA;

Aduro Biotech Inc Berkeley CA USA;

Johns Hopkins Sch Med Dept Oncol Baltimore MD USA;

Oregon Hlth &

Sci Univ Knight Canc Inst Dept Cell Dev &

Canc Biol Portland OR 97201 USA;

Aduro Biotech Inc Berkeley CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma [J] . Hassan Raffit, Alley Evan, Kindler Hedy, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第19期

机译：患有宫廷素（CRS-207）的活衰减，患有恶性胸膜间皮瘤患者的临床响应
2. Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM) [J] . Raffit Hassan, Evan Alley, Hedy Kindler, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：抗-间皮素疫苗CRS-207联合或不联合低剂量环磷酰胺加化学疗法作为恶性胸膜间皮瘤（MPM）的一线治疗
3. Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors [J] . Dirk G Brockstedt, Dung T Le, Raffit Hassan, Journal for ImmunoTherapy of Cancer . 2013,第S1期

机译：针对表达间皮素的肿瘤的减毒双缺失（LADD）单核细胞增生李斯特氏菌的临床经验
4. Feasibility trial assessing intrapleural photodynamic therapy combined with pleurectomy/decortication then chemotherapy in malignant pleural mesothelioma patients. [C] . Serge Mordon, Camille Munck, Ecaterina Surmei-Pintilie, International Photodynamic Association World Congress . 2019

机译：可行性试验评估腹膜内光动力学治疗与胸膜切除术/凝固患者患者在恶性胸膜间皮瘤患者中相结合。
5. An economic analysis of the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma. [D] . Malacan, Jean. 2016

机译：恶性胸膜间皮瘤患者在标准化疗中加用贝伐单抗的经济分析。
6. Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM) [O] . Raffit Hassan, Evan Alley, Hedy Kindler, 2015

机译：抗-间皮素疫苗CRS-207联合或不联合低剂量环磷酰胺加化学疗法作为恶性胸膜间皮瘤（MPM）的一线治疗
7. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma [O] . Raffit Hassan, Evan Alley, Hedy Kindler, 2019

机译：患有宫廷素（CRS-207）的活衰减，患有恶性胸膜间皮瘤患者的临床响应

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

摘要

著录项

相似文献

相关主题

期刊订阅